دورية أكاديمية
أعرض في EDS

Design, Synthesis, and Evaluation of B -(Trifluoromethyl)phenyl Phosphine-Borane Derivatives as Novel Progesterone Receptor Antagonists.

التفاصيل البيبلوغرافية
العنوان: Design, Synthesis, and Evaluation of B -(Trifluoromethyl)phenyl Phosphine-Borane Derivatives as Novel Progesterone Receptor Antagonists.
المؤلفون: Miyajima Y; Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan., Ochiai K; Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan., Fujii S; Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan.
المصدر: Molecules (Basel, Switzerland) [Molecules] 2024 Apr 02; Vol. 29 (7). Date of Electronic Publication: 2024 Apr 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c1995-
مواضيع طبية MeSH: Receptors, Progesterone* , Boranes*/pharmacology , Phosphines*, Computer Simulation ; Drug Discovery
مستخلص: We previously revealed that phosphine-boranes can function as molecular frameworks for biofunctional molecules. In the present study, we exploited the diversity of available phosphines to design and synthesize a series of B -(trifluoromethyl)phenyl phosphine-borane derivatives as novel progesterone receptor (PR) antagonists. We revealed that the synthesized phosphine-borane derivatives exhibited Log P values in a predictable manner and that the P-H group in the phosphine-borane was almost nonpolar. Among the synthesized phosphine-boranes, which exhibited PR antagonistic activity, B -(4-trifluoromethyl)phenyl tricyclopropylphosphine-borane was the most potent with an IC 50 value of 0.54 μM. A docking simulation indicated that the tricyclopropylphosphine moiety plays an important role in ligand-receptor interactions. These results support the idea that phosphine-boranes are versatile structural options in drug discovery, and the developed compounds are promising lead compounds for further structural development of next-generation PR antagonists.
References: Steroids. 2011 Jun;76(7):636-52. (PMID: 21414337)
J Med Chem. 2002 Sep 26;45(20):4379-82. (PMID: 12238914)
Sci Rep. 2017 Mar 03;7:42717. (PMID: 28256516)
J Steroid Biochem. 1984 Jan;20(1):271-6. (PMID: 6708512)
Endocrinology. 1993 Jun;132(6):2622-30. (PMID: 8504763)
J Med Chem. 2011 Oct 27;54(20):7055-65. (PMID: 21916484)
Bioorg Med Chem Lett. 2009 Aug 15;19(16):4777-80. (PMID: 19595590)
ACS Med Chem Lett. 2018 Jun 23;9(7):641-645. (PMID: 30034593)
Eur J Med Chem. 2014 Sep 12;84:264-77. (PMID: 25036787)
Bioorg Med Chem. 2014 Oct 1;22(19):5329-37. (PMID: 25151087)
Molecules. 2021 Apr 25;26(9):. (PMID: 33923006)
ACS Med Chem Lett. 2016 Sep 15;7(12):1028-1033. (PMID: 27994732)
Cancer Res. 1987 Dec 15;47(24 Pt 1):6560-4. (PMID: 3677094)
Drug Discov Today Technol. 2004 Dec;1(4):337-41. (PMID: 24981612)
Steroids. 2003 Nov;68(10-13):981-93. (PMID: 14667991)
Theranostics. 2016 Feb 13;6(4):533-44. (PMID: 26941846)
Cell. 1995 Dec 15;83(6):835-9. (PMID: 8521507)
Chemistry. 2007;13(24):6920-31. (PMID: 17525921)
J Med Chem. 2008 Mar 27;51(6):1861-73. (PMID: 18318463)
Psychoneuroendocrinology. 2018 Jul;93:8-19. (PMID: 29680774)
Clin Cancer Res. 2007 Jun 1;13(11):3370-9. (PMID: 17545545)
Curr Med Chem. 2001 Aug;8(10):1147-55. (PMID: 11472233)
J Comput Chem. 2009 Dec;30(16):2785-91. (PMID: 19399780)
Chem Rev. 2007 Nov;107(11):4746-96. (PMID: 17967037)
Nat Rev Cancer. 2013 Jun;13(6):385-96. (PMID: 23702927)
Int J Mol Sci. 2022 Jul 20;23(14):. (PMID: 35887338)
Steroids. 2008 Aug;73(7):689-701. (PMID: 18472121)
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26. (PMID: 11259830)
J Mol Endocrinol. 2020 Jul;65(1):T15-T33. (PMID: 32599565)
Exp Eye Res. 2006 Nov;83(5):1252-9. (PMID: 16934805)
Steroids. 2018 May;133:75-81. (PMID: 29317254)
Endocr Rev. 2020 Oct 1;41(5):. (PMID: 32365199)
Bioorg Med Chem. 2020 Feb 15;28(4):115310. (PMID: 31980362)
Maturitas. 2008 Sep-Oct;61(1-2):151-7. (PMID: 19434887)
Endocrinology. 2005 Aug;146(8):3577-88. (PMID: 15878961)
Bioorg Med Chem. 2015 Feb 15;23(4):803-9. (PMID: 25593098)
Curr Med Res Opin. 2015 Jan;31(1):1-12. (PMID: 25365466)
Cancer Res. 1991 Aug 15;51(16):4470-5. (PMID: 1868468)
Cancer Lett. 2016 Jul 1;376(2):310-7. (PMID: 27080304)
Bioorg Med Chem Lett. 2004 May 3;14(9):2185-9. (PMID: 15081005)
Endocr Rev. 2013 Feb;34(1):130-62. (PMID: 23303565)
Chem Rev. 2010 Jul 14;110(7):4023-78. (PMID: 20672859)
J Med Chem. 2005 Aug 11;48(16):5092-5. (PMID: 16078826)
RSC Med Chem. 2023 Oct 2;15(1):119-126. (PMID: 38283218)
معلومات مُعتمدة: 23K0604 Japan Society for the Promotion of Science; none Takeda Science Foundation; none Hoansha Fundation; JP23ama121043 Japan Agency for Medical Research and Development; none the Research Center for Biomedical Engineering
فهرسة مساهمة: Keywords: antagonist; hydrophobicity; phosphine–borane; phosphorus; progesterone receptor; structural optimization
المشرفين على المادة: FW6947296I (phosphine)
0 (Receptors, Progesterone)
0 (Boranes)
0 (Phosphines)
تواريخ الأحداث: Date Created: 20240413 Date Completed: 20240415 Latest Revision: 20240425
رمز التحديث: 20240425
مُعرف محوري في PubMed: PMC11013038
DOI: 10.3390/molecules29071587
PMID: 38611867
قاعدة البيانات: MEDLINE
الوصف
تدمد:1420-3049
DOI:10.3390/molecules29071587